Stock analysis, AI verdict, fundamentals & technical signals
Rating: HOLD
Price: $55.52 Analyst target: $64.65 Upside: 16.44%
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
See the full interactive analysis & chart →Informational only — not investment advice.